Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders

References

• Vardiman JW, Brunning RD, Harris NL. Myelodysplastic/ myeloproliferative diseases: introduction. In: Jaffe ES, Harris NL, Stein H et al. (eds) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001. World Health Organization Classification of Tumours, 2001; 3: 47–48.
   Google Scholar
• Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutations of thetyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144–1148.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J et al. Activating mutation in thetyrosine kinase JAK2 in polycithemia vera, essential thrombocy-temia, and metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Dewald GW, Lasho TL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syn-dromes. Blood 2005; 106: 1207–1209.
   PubMed Web of Science ®Google Scholar
• Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant 2007; 13: 64–72.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313–320.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.
   PubMed Web of Science ®Google Scholar
• Hermouet S, Dobo I, Lippert E et al. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F). Leukemia 2007; 21: 1128–1130.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New Engl J Med 2005; 353: 33–45.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Barbui T et al. Leukocytosis as a majorthrombotic risk factor in patients with polycythemia vera. Blood 2007; 109: 2446–2452.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Hematol 2005; 113: 213–219.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Lasho TL, Schwager SM et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131; 208–213.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pancrazzi A et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849.
   PubMed Web of Science ®Google Scholar
• Basquiera AL, Fassetta F, Soria N, Barral JM, Ricchi B, Garcia H. Accuracy of leukocyte alkaline phosphatase score to predict JAK2 V617F mutation. Haematologica 2007; 92: 704–705.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–136.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Schwager SM et al. The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 2005; 131: 320–328.
   PubMed Web of Science ®Google Scholar
• Heller PG, Lev PR, Salim JP et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 2006; 77: 210–216.
   PubMed Web of Science ®Google Scholar
• Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006; 132: 244–245.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J et al. Efficacy and safety of low-dose aspirin in polycythemia vera. New Engl J Med 2004; 350: 114–124.
   PubMed Web of Science ®Google Scholar
• Bellucci S, Michiels. J.J. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersen-sitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 2006; 32: 381–398.
   PubMed Web of Science ®Google Scholar
• Robertson B, Urquhart C, Ford I et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007; 5: 1679–1685.
   PubMed Web of Science ®Google Scholar
• Rossi D, Deambrogi C, Capello D et al. JAK2 V617F mutation in leukaemic transformation of Philadelphia-negative chronic myelo-proliferative disorders. Br J Haematol 2006; 15: 264–275.
   Google Scholar
• Werning G, Mercher T, Okabe R, Levine RL, Lee BH, Gililland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274–4281.
   PubMed Web of Science ®Google Scholar
• Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to CMD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652–1660.
   PubMed Web of Science ®Google Scholar
• Zhang Si, Li JY, Song JH, XU W, Qiu HX. The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identifica-tion of a novel C616Y point mutation in a PV patient. Int Jnl Lab Hem 2007; 29: 71–72.
   PubMed Web of Science ®Google Scholar
• Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007; 110: 2768–2769.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Bacher U, Kern W, Schröder M, Haferlach T, Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 2006; 20: 2195–2197.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960–1963.
   PubMed Web of Science ®Google Scholar
• Scott LM, Beer PA, Bench Ai, Erber WN, Green AR. Prevalence of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007; 139: 511–512.
   PubMed Web of Science ®Google Scholar